Future prospects for therapeutic strategies for brain metastases and acquired resistance in the treatment of ALK positive advanced non small cell lung cancer. A comprehensive literature review with network meta-analysis.
Not Applicable
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000049680
- Lead Sponsor
- Showa University school of medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Studies for children Observational studies
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms drive acquired resistance to ALK inhibitors in brain metastases of ALK-positive NSCLC?
How do next-generation ALK inhibitors from Roche and Takeda compare to crizotinib in managing brain metastases in ALK-positive NSCLC patients?
Which biomarkers predict response to ALK-targeted therapies in patients with brain metastases and acquired resistance?
What are the safety profiles of lorlatinib and ceritinib in treating ALK-positive NSCLC with brain metastases?
How do combination therapies with ALK inhibitors and immunotherapy impact outcomes in ALK-positive NSCLC with brain metastases?